Published in Kidney Int on May 21, 2008
Age and association of kidney measures with mortality and end-stage renal disease. JAMA (2012) 7.20
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol (2010) 1.75
Genetic deficiency of adiponectin protects against acute kidney injury. Kidney Int (2013) 1.71
Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol (2009) 1.58
Adiponectin: good, bad, or just plain ugly? Kidney Int (2008) 1.48
A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet (2010) 1.38
Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther (2013) 1.22
Adiponectin dysregulation and insulin resistance in type 1 diabetes. J Clin Endocrinol Metab (2012) 1.10
Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis (2011) 1.10
The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis (2010) 1.05
Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines. Cardiol Res Pract (2011) 0.96
Proinflammatory cytokines, adiponectin, and increased risk of primary cardiovascular events in diabetic patients with or without renal dysfunction: results from the ESTHER study. Diabetes Care (2013) 0.95
Discovery and validation of serum protein changes in type 1 diabetes patients using high throughput two dimensional liquid chromatography-mass spectrometry and immunoassays. Mol Cell Proteomics (2011) 0.91
Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. Kidney Int (2014) 0.88
The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. BMC Nephrol (2013) 0.87
Association of adiponectin and leptin with relative telomere length in seven independent cohorts including 11,448 participants. Eur J Epidemiol (2014) 0.81
The serum vaspin levels are reduced in Japanese chronic hemodialysis patients. BMC Nephrol (2012) 0.80
Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease. Nephrol Dial Transplant (2014) 0.78
Serum adiponectin helps to differentiate type 1 and type 2 diabetes among young Asian Indians. Diabetes Technol Ther (2013) 0.78
Association of Plasma Adiponectin and Oxidized Low-Density Lipoprotein with Carotid Intima-Media Thickness in Diabetic Nephropathy. J Diabetes Res (2015) 0.77
The adiponectin rs17300539 G>A variant and nephropathy risk. Kidney Int (2008) 0.77
Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia. Mol Syst Biol (2015) 0.76
Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia. Mol Syst Biol (2015) 0.76
AMPK Activators as a Drug for Diabetes, Cancer and Cardiovascular Disease. Pharm Regul Aff (2014) 0.75
Expression of Adiponectin Receptors on Peripheral Blood Leukocytes of Hypertensive Children Is Associated with the Severity of Hypertension. Biomed Res Int (2015) 0.75
ATP-dependent potassium channels are implicated in simvastatin pretreatment-induced inhibition of apoptotic cell death after renal ischemia/reperfusion injury. Med J Islam Repub Iran (2015) 0.75
Subattomole detection of adiponectin in urine by ultrasensitive ELISA coupled with thio-NAD cycling. Biophys Physicobiol (2015) 0.75
Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease. Diabetologia (2016) 0.75
Association of serum adiponectin concentration with aortic arterial stiffness in chronic kidney disease: from the KNOW-CKD study. Clin Exp Nephrol (2016) 0.75
Adiponectin in children and young adults with focal segmental glomerulosclerosis. Pediatr Nephrol (2015) 0.75
Downregulation of AdipoR1 is Associated with increased Circulating Adiponectin Levels in Serbian Chronic Kidney Disease Patients. J Med Biochem (2016) 0.75
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06
Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 18.27
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (2012) 5.10
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet (2012) 4.75
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Prevention and early detection of vascular complications of diabetes. BMJ (2006) 4.14
Nephropathy in diabetes. Diabetes Care (2004) 4.08
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int (2011) 3.96
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int (2003) 3.95
Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest (2002) 3.86
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology (2003) 3.59
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care (2003) 3.12
Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int (2002) 2.92
Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation (2005) 2.81
Coordinated collagen and muscle protein synthesis in human patella tendon and quadriceps muscle after exercise. J Physiol (2005) 2.75
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis (2003) 2.68
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ (2004) 2.62
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int (2011) 2.52
Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab (2006) 2.52
Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol (2006) 2.51
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int (2004) 2.42
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant (2002) 2.41
Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology (2009) 2.39
Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. J Hypertens (2007) 2.27
Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens (2013) 2.15
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med (2009) 2.14
Urinary proteomics in diabetes and CKD. J Am Soc Nephrol (2008) 2.12
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens (2007) 2.12
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care (2003) 2.08
Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care (2010) 2.06
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension (2011) 2.05
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis (2011) 2.05
Progression of nephropathy in type 2 diabetic patients. Kidney Int (2004) 2.05
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int (2005) 2.00
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Diabetic nephropathy. Diabetes Care (2003) 1.87
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation (2011) 1.87
Whey and casein labeled with L-[1-13C]leucine and muscle protein synthesis: effect of resistance exercise and protein ingestion. Am J Physiol Endocrinol Metab (2010) 1.82
New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet (2012) 1.79
Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes (2009) 1.76
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol (2009) 1.75
From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev (2004) 1.74
Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes (2005) 1.71
Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes (2002) 1.69
Low IGF-I and elevated testosterone during puberty in subjects with type 1 diabetes developing microalbuminuria in comparison to normoalbuminuric control subjects: the Oxford Regional Prospective Study. Diabetes Care (2003) 1.68
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int (2012) 1.65
Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. Eur Heart J (2007) 1.63
Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens (2009) 1.61
Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care (2002) 1.61
Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab (2006) 1.61
Adiponectin and lipoprotein particle size. Diabetes Care (2009) 1.60
Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes (2004) 1.59
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care (2002) 1.57
The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care (2006) 1.52
Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Kidney Int (2005) 1.52
Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care (2003) 1.51
Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant (2004) 1.49
Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab (2007) 1.49